Clene Inc. (CLNN): Price and Financial Metrics
GET POWR RATINGS... FREE!
CLNN POWR Grades
- Sentiment is the dimension where CLNN ranks best; there it ranks ahead of 77.55% of US stocks.
- The strongest trend for CLNN is in Growth, which has been heading up over the past 177 days.
- CLNN ranks lowest in Quality; there it ranks in the 10th percentile.
CLNN Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for CLNN is -0.05 -- better than merely 6.64% of US stocks.
- With a price/sales ratio of 219.1, CLENE INC has a higher such ratio than 98.32% of stocks in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 41.63 for CLENE INC; that's greater than it is for 99.21% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to CLENE INC are WVE, AGEN, DCTH, INBX, and RETA.
- Visit CLNN's SEC page to see the company's official filings. To visit the company's web site, go to clene.com.
CLNN Valuation Summary
- CLNN's price/sales ratio is 251.1; this is 12148.78% higher than that of the median Healthcare stock.
- Over the past 54 months, CLNN's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for CLNN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CLNN | 2023-01-20 | 251.1 | -11.8 | -4.5 | -5.9 |
| CLNN | 2023-01-19 | 269.6 | -12.7 | -4.8 | -6.3 |
| CLNN | 2023-01-18 | 268.0 | -12.6 | -4.8 | -6.3 |
| CLNN | 2023-01-17 | 252.7 | -11.9 | -4.5 | -5.9 |
| CLNN | 2023-01-13 | 220.8 | -10.4 | -4.0 | -5.3 |
| CLNN | 2023-01-12 | 207.3 | -9.7 | -3.7 | -5.0 |
CLNN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CLNN has a Quality Grade of C, ranking ahead of 43.21% of graded US stocks.
- CLNN's asset turnover comes in at 0.009 -- ranking 398th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows CLNN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.009 | -0.488 | -4.664 |
| 2021-03-31 | 0.008 | 0.265 | -4.985 |
| 2020-12-31 | 0.004 | 0.684 | -0.857 |
| 2020-09-30 | 0.004 | 0.672 | -1.086 |
| 2020-09-30 | 0.004 | 0.672 | -1.086 |
| 2020-06-30 | 0.002 | 0.266 | -0.605 |
CLNN Price Target
For more insight on analysts targets of CLNN, see our CLNN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $22.75 | Average Broker Recommendation | 1.4 (Strong Buy) |
CLNN Stock Price Chart Interactive Chart >
CLNN Price/Volume Stats
| Current price | $1.47 | 52-week high | $5.13 |
| Prev. close | $1.30 | 52-week low | $0.87 |
| Day low | $1.33 | Volume | 150,900 |
| Day high | $1.49 | Avg. volume | 165,567 |
| 50-day MA | $1.12 | Dividend yield | N/A |
| 200-day MA | $2.29 | Market Cap | 108.52M |
Clene Inc. (CLNN) Company Bio
Clene Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of unique therapeutics for neurodegenerative diseases. Clene provides nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs.
Latest CLNN News From Around the Web
Below are the latest news stories about CLENE INC that investors may wish to consider to help them evaluate CLNN as an investment opportunity.
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23SALT LAKE CITY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced that it will participate in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow Series on January 18 and January 23. The Company welcomes stakeholders, investors, and other interested parties to register and attend these free live events. Rob Etherington, |
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAgPrimary endpoint of time to substantial symptom resolution was not met in acutely symptomatic, non-hospitalized COVID-19 patientsCNM-ZnAg treatment was safe and well-tolerated SALT LAKE CITY, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced topline study results from its Phase 2 investigational trial with CNM-ZnAg, an ionic solution |
Clene Announces Closing of $5 Million Debt Facility from the State of MarylandFunding Demonstrates Importance of Working with Private Sector to Improve Lives of Marylanders, says Governor HoganSALT LAKE CITY, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the closing of a $5 million debt facility (the “Loan”) with the Maryland Department |
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying TherapiesCNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating disease modifying therapies (DMTs)No approved MS DMTs have shown global neurological improvement in stable MS patients, a significant unmet medical need in MSCNM-Au8 treatment was well-tolerated, and no significant safety findings were observed SALT LAKE CITY, Nov. 28, |
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP) and Clene (CLNN)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Adaptimmune Therapeutics (ADAP – Research Report) and Clene (CLNN – Research Report). Adaptimmune Therapeutics (ADAP) Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Adaptimmune Therapeutics today and set a price target of $9.00. The company's shares closed last Tuesday at $1.78, close to its 52-week low of $1.01. According to TipRanks. |
CLNN Price Returns
| 1-mo | 54.74% |
| 3-mo | 45.54% |
| 6-mo | -56.76% |
| 1-year | -44.74% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 47.00% |
| 2022 | -75.61% |
| 2021 | -54.50% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...